Considering the importance of sexual function, high prevalence of sexual dysfunction (especially dyspareunia caused by atrophic vaginitis) in breastfeeding women, and lack of effective interventions, the present research aimed to determine the effect of oxytocin (OXT) vaginal gel on sexual function (primary outcome), sexual satisfaction, and depression (secondary outcomes) in the breastfeeding women.
Methods
This randomized triple-blind controlled trial was conducted on 64 breastfeeding women who referred to health centers in the city of Tabriz, Iran, in 2020-21. Participants were equally assigned to intervention/control groups using block randomization. 200 IU of OXT vaginal gel was given to the participants in the intervention group daily for eight week and the same protocol was carried out for the control group with placebo. Standard questionnaires of Female Sexual Function Index (FSFI), Edinburgh Postpartum Depression Scale (EPDS) and Sexual satisfaction scale for women (SSSW) were completed at baseline and 8 weeks after intervention. ANCOVA test was used to compare post-intervention mean score of the groups, adjusted for the baseline values.
Results
After intervention, there was no statistically significant difference between groups in terms of mean total score of FSFI (Adjusted Mean Difference (AMD): 1.14; 95% Confidence Interval (95% CI): -1.28 to 9.16; P= 0.349) and sexual satisfaction (AMD: 5.01; 95% CI: -0.53 to 10.56; P= 0.075). However, there was statistically significant difference between the groups in terms of mean scores of sexual contentment (AMD: 1.56; 95% CI: 0.29 to 2.83; P = 0.017) and depression (AMD: -1.90; 95% CI: -1.27 to -2.54; P < 0.001). One participant in the OXT group and one participant in the placebo group reported mild uterine contraction and one person in the placebo group reported vaginal burning sensations.
Conclusions
No evidence was found for the effects of OXT gel in the improvement of FSFI, even though, OXT significantly improved sexual satisfaction in the domain of contentment, and improved the symptoms of depression in comparison to the placebo group. However, a definite conclusion requires more research in this regard.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
OXT
Oxytocin
FSFI
Female Sexual Function Index
EPDS
Edinburgh Postpartum Depression Scale
SSSW
Sexual Satisfaction Scale for Women
AMD
Adjusted mean difference
FSD
Female sexual dysfunction
HRT
Hormone replacement therapy
HPA
hypothalamic–pituitary–adrenal
IRCT
Iranian Registry of Clinical Trials
BMI
Body mass index
POF
Premature ovarian failure
Background
Pregnancy and childbirth cause hormonal and physical changes in the person and exert considerable effects on the health of the mothers and the quality of their lives [1]. Sexual function undergoes changes during the disparate periods of a woman’s life and one of these periods that is less considered is the postpartum period [2]. The changes during the postpartum period include pain during coitus, reduction or lack of sexual desire, and failure to achieve orgasm [3]. The studies indicated that 91% of women suffer from sexual problems during the postpartum period, especially loss of sexual desire, dyspareunia, and atrophic vaginitis [4, 5].
Sexual satisfaction is one of the physiological needs that leads to human health. Lack of sexual satisfaction, and physical and psychological pressures caused by it can result in disorders and reduce a person’s capabilities as well as creativity [7]. Sexual dysfunction is a chain of sexual-psychological disorders [6]. The results of the review of the literature indicated that there is a bilateral relationship between female sexual dysfunction (FSD) and depression [8‐10]. Both sexual dysfunction and depression are more prevalent in women, during the postpartum period [11, 12]. The results of Natsal-3 cohort study showed that depression is one of the most prevalent common diseases with FSD [13]. As a result, simultaneous screening in people with FSD and women who gave birth recently is considerably important [3].
Anzeige
A variety of methods were employed in order to prevent and treat FSD. Hormone replacement therapy (HRT) is one of the most common methods for improving the sexual function. However, these drugs (especially estradiol) cannot be used by breastfeeding mothers since they have a considerable impact on the quality and quantity of the breast milk. Treatment with topical lubricant gels is one of the methods used during breastfeeding with no enough effect [7]. One of the hormones recently studied by researchers to treat sexual disorder is the oxytocin (OXT) hormone. Besides fewer side effects, this method can lead to more benefits than the common systematic and topical treatments [14‐18].
OXT is a nine-amino-acid peptide hormone produced in the supraoptic and paraventricular nucleus of the hypothalamus and released into blood flow through the posterior pituitary [18]. The most known performance of OXT is during the start and progression of the process of childbirth and facilitation of milk secretion after childbirth [16]. OXT has a crucial role in regulating the mood, forming social interactions, mother-child attachment, and creating a sense of trust and intimacy in the interpersonal and marital relationship. OXT operates centrally in the central nervous system and environmentally in various tissues such as the ovary, testis, gastrointestinal system, and cardiovascular system through OXT receptors [19‐22].
Several studies argued that disruption in the hormones secreted from the hypothalamic–pituitary–adrenal (HPA) axis can cause sexual dysfunction. Some studies have shown positive effect of intranasal OXT on the intensity of orgasm, arousal, and sexual satisfaction in women and men with sexual dysfunction [23‐26]. One of the key mechanisms of OXT is stimulating the growth of natural cells in the body, which operates as a growth factor similar to growth factors of nerves and insulin. Furthermore, in the laboratory and animal tests, OXT restored the ulcers and damages to environmental nerves and recovered the skin and epithelium of the vagina through anti-inflammatory processes and secreting inflammatory cytokines. OXT accelerates the scar healing process of various cells through mechanisms such as increasing the tissue perfusion, increasing the secretion of the disparate growth factors, and stimulation of mitosis. Effective factors on reducing or improving the symptoms of atrophic vaginitis might follow a similar path [18, 27].
Taking into account the already stated mechanism of action of this hormone, psychologists and sex therapists recently become interested in this subject. Therefore, prescribing exogenous OXT may reduce and improve sexual disorders, especially sexual dysfunction caused by atrophic vaginitis in breastfeeding women. The present research aimed to determine the effect of OXT vaginal gel on sexual function (primary outcome), sexual satisfaction, and depression (secondary outcomes) in the breastfeeding mothers.
Anzeige
Methods
Study design and participants
This is a randomized, placebo-controlled, triple-blind trial. The trial conducted on breastfeeding women covered by the health centers in the city of Tabriz, Iran, in 2020-21. The participants, outcome assessors, and data analysts were not aware of the interventions received by each participant.
Participants were married healthy breastfeeding women (with no records of childbirth complications or illness), with a constant and healthy sexual partner, were sexually active, and 6 weeks to 6 months had passed from their childbirth. Women who obtained a score of less than 28 in the Female Sexual Function Index (FSFI) and a score of less than 13 in the Edinburgh Postpartum Depression Scale (EPDS) were included in the study. Use of highly effective contraceptive method was another inclusion criterion. The exclusion criteria were being pregnant, having postpartum depression, consumption of antidepressants and other nervous system drugs, hormonal treatment due to female sexual dysfunction, pelvic radiotherapy and chemotherapy, or any uncontrolled and chronic disease such as diabetes.
Sample size
The sample size was calculated in accordance with the sexual function variable and using G-Power software. According to the study by Sehhatie et al., [28] regarding the sexual function and by considering M1=16.4 (pre-intervention mean) and M2=19.68 (assuming a 20% increase due to intervention), SD1=SD2=4.3, α = 0.05, Power=90%, sample size was calculated to be equal to 31 participants in each group. The total final sample size amounted to 34, taking into account 10% attrition.
Sampling
After approval of the Ethics Committee of Tabriz University of Medical Sciences (IR.TBZMED.REC.1396.715), and registration of the study in the Iranian Registry of Clinical Trials (IRCT20120718010324N32), the researcher attended the health centers in the city of Tabriz-Iran for sampling. There are 80 health centers in Tabriz city. Participants were selected from the ten crowded centers with different socio-economic classes. Information of all women, either pregnant or who gave birth, was available in the household health information system. The principal investigator (AM) extracted phone number of potentially eligible women from the system, contacted and explained them the objectives of the study, and invited them to attend the health center. Women who were willing to participate were included in the study after assessing the inclusion and exclusion criteria and obtaining the written informed consent. Then, the scales were completed by all participants. Furthermore, anthropometric indices were calculated including weight and height (to measure the body mass index (BMI)), waist circumference, and blood pressure.
Randomization and intervention
The participants were randomly assigned into two groups (recipient of OXT or placebo vaginal gel) via the www.random.org website and using block randomization with block sizes of 8 and 10. In order to conceal allocation, the drug/placebo was packaged in identical consecutively numbered packages. The allocation generation and preparation of the packages were carried out by a person not involved in the processes of data collection and analysis.
Raw materials of OXT were supplied from the Caspian Tamin Pharmaceutical Company. The gel and the placebo were prepared in the Faculty of Pharmacy of Tabriz University of Medical Science. Placebo was a water-based gel with neutral pH that was contained carbomer 934, Methyl and propyl paraben as a preservative (prevent from growth of microorganisms). OXT gel was exactly the same as placebo, except that it contains 200 IU of the active ingredient OXT powder. Each IU of OXT is equivalent to 1.67 µg, so 200 IU of OXT is equal to 344 µg. The placebo gel and tubes were exactly the same color, odor and size as OXT gel and tubes. In the present research, 200 IU of OXT vaginal gel was given to the women in the intervention group once a day for eight weeks and the same protocol was carried out for the control group with placebo drug. Drug/placebo gel was used by the participants using applicators at any hour of the day and with the maximum of half an hour prior to sexual intercourse. Four OXT or placebos gel tubes were provided for each participant, and an OXT or placebo gel tube were delivered to the participants once every two weeks in the health centers. Therefore, the investigator followed-up the participants once every two weeks to remind and to emphasize regular consumption of the drugs.
Tools
The data were collected using the sociodemographic and obstetrics information questionnaire, FSFI, Sexual satisfaction scale for women (SSSW), EPDS, and a checklist of the side effects. The Persian version of the EPDS, FSFI and SSSW have been approved in Iran after obtaining permit from the copyright holders of the English version of the scales. The used scales are available as Appendix.
FSFI
FSFI is a standard and international self-report tool used for the assessment of the sexual function of women, which was first designed by Rosen [29]. This questionnaire contains 19 items that measure women’s sexual function in six domains. Each domain includes the following weight coefficient and a number of items. Sexual desire (2 items*0.6), arousal (4 items*0.4), lubrication (4 items*0.4), orgasm (3 items*0.3), satisfaction (3 items*0.3), and pain (3 items*0.3). The total score of FSFI was obtained from the sum of the scores at each domain and considering their specific coefficients. The total sexual function score ranged between 2 and 36. FSFI<28 was considered as sexual dysfunction. In this index, the highest score shows the desirable sexual function. The validity and reliability of FSFI were confirmed by Fakhri et al. and Mohammadi et al. in Iran [30, 31].
Anzeige
SSSW
In the present research, the SSSW was used to measure women’s sexual satisfaction, which included 30 questions in five domains: contentment (questions 1 to 6), communication (questions 7 to 12), compatibility (questions 13 to 18), relational concern (questions 19 to 24), and personal concern (questions 25 to 30). In this questionnaire, the 5 points Likert scale was used, i.e. absolutely agree 1 point, agree 2 points, I don’t know 3 points, disagree 4 points, absolutely disagree 5 points. Inverted scoring was used for questions 1, 4, 5, 6, 9, 10, 11, and 12. The score of each domain were obtained using sum score of related questions; with the higher score, the more sexual satisfaction. The validity and reliability of this tool were confirmed by Roshan Chesli et al. [32].
EPDS
EPDS was employed for the assessment of depression. It was designed by Cox et al. [33] and is used to measure pregnancy and postpartum depression. This tool includes 10 questions with four options scored 0-3. In some questions, the order of the options was from less to high severe (items 1, 2, and 4) and some were ordered from high to low (items 10, 9, 8, 7, 6, 5, and 3). The total score which is varied from zero to 30, is obtained from summing up the question scores. Those with score of higher than 12 suffer from depression. The validity and reliability of this scale were approved by Montazeri et al. [34].
Checklist of side effects
In the present research, the side effects were extracted through searching from scientific data bases and literature review and were listed in a checklist which included nausea, vomiting, headache, uterine contractions, vaginal itching and burning sensations. Any reported side effects by participants were also recorded.
Medication recording checklist
To assess compliance with the medication, the participants were requested to record their intake of the gel in a medication recording checklist. The checklist was provided to participants in the first visit. Also for assessing adherence to treatments, telephone calls were made weekly to emphasis the regular use of the medications and assess the side effects and potential withdrawals.
Anzeige
Data analysis
The data were analyzed using SPSS software version 24. Kolmogorov-Smirnov test was used to determine the normality of the quantitative data. All data had normal distribution. After the intervention, ANCOVA test adjusted for the baseline scores was used to compare the mean scores of sexual function, sexual satisfaction and depression between groups. Mann Whitney U test was used to compare the change in depression score (EPDS at 8 weeks - EPDS at baseline) between the two groups as a sensitivity analysis to confirm the results. Subgroup analysis was done based on the delivery type by using ANCOVA test. The Mann Whitney U test and subgroup analyses were post-hoc, following reviewers’ suggestions. The level of significance was considered less than 0.05.
Results
Baseline characteristics
All 200 breastfeeding women selected from the health centers’ electronic system underwent screening in terms of eligibility criteria in the first assessment. Among them, 44 women were excluded from the study due to medical problems and childbirth complications, consumption of drugs affecting sexual function, and problems pertinent to the child, and 46 people were not interested in participating in the study. 64 out of 100 participants who fulfilled the FSFI questionnaire were identified as having sexual dysfunction (FSFI<28) and included in the study. The rest of questionnaires were completed after obtaining informed written consent. The participants were randomly assigned into two groups, i.e. OXT vaginal gel group (n = 34) and the placebo group (n = 30). There was no loss to follow-up and all participants in both groups continued the intervention up to eight weeks. After completion of the study, all questionnaires were filled in by the participants (Fig. 1).
Fig. 1
Flowchart of the study
×
Table 1 shows the socio-demographic and obstetrics characteristics of the participants by their groups. There was no statistically significant difference between the two groups except of age (P > 0.05). The variable of age was adjusted in the ANCOVA models.
Table 1
Socio-demographic and obstetrics characteristic of the participants in the study groups
Variables
Oxytocin (n = 34)
Placebo (n = 30)
Number (Percent)
Number (Percent)
Age (year) a
31.2 (5.1)
27.8 (5.9)
Level of education
Illiterate
1 (2.9)
2 (6.7)
Elementary
6 (17.6)
1 (3.3)
Secondary
5 (14.7)
10 (33.3)
High school
3 (8.8)
8 (26.7)
Diploma
9 (26.5)
5 (16.7)
University
10 (29.4)
4 (13.3)
Spouse’s Education
Illiterate
Elementary
6 (1.6)
6 (20.0)
Secondary
7 (20.6)
7 (23.3)
High school
5 (14.7)
2 (6.7)
Diploma
6 (17.6)
10 (33.3)
University
10 (29.4)
5 (16.7)
Job
Housekeeper
27 (79.4)
28 (93.3)
Employed indoors
1 (2.9)
1 (3.3)
Employed outdoors
6 (17.6)
1 (3.3)
Spouse’s Job
Unemployed
0 (0)
1 (3.3)
Worker
4 (11.8)
10 (33.3)
Retired
1 (2.9)
0 (0)
Self employed
20 (58.8)
15 (50)
Private sector employee
2 (5.9)
0 (0)
Public sector employee
7 (20.6)
4 (13.3)
Parity
1
11 (32.4)
9 (30.1)
2
12 (35.3)
18 (60)
3
8 (23.5)
3 (10)
4
2 (5.9)
0 (0)
5
1 (2.9)
0 (0)
Delivery type
Vaginal with episiotomy
10 (29.4)
14 (46.7)
Vaginal without episiotomy
0 (0)
3 (10.0)
Elective cesarean section
16 (47.1)
9 (30.0)
Emergency cesarean section
8 (23.5)
4 (13.3)
Abortion
Yes
10 (29.4)
13 (43.3)
No
24 (70.6)
17 (56.7)
Family Members number
1-3
21 (61.8)
17 (56.7)
4-6
11 (32.4)
10 (3.33)
>6
2 (5.9)
3 (10)
Sufficiency of monthly income
Inadequate
7 (20.6)
7 (23.3)
Relatively adequate
25 (73.5)
21 (70)
More than adequate
2 (5.9)
2 (6.7)
Life satisfaction
Satisfied
28 (482)
29 (96.7)
No idea
4 (11.8)
14 (3.3)
Dissatisfied
2 (5.9)
0 (0)
Live with spouse’s family
Yes
6 (17.6)
11 (36.7)
No
28 (82.4)
19 (63.3)
Spouse’s smoking
Yes
11 (32.4)
11 (36.7)
No
23 (67.67)
19 (63.3)
Infant other nutrition
Yes
20 (58.8)
11 (36.7)
No
14 (41.2)
19 (63.3)
Infant age (Month)
4.18 (1.88)
3.87 (1.72)
Waist circumferencea (cm)
77.18 (13.06)
75.50 (11.69)
Hip circumferencea (cm)
93.35 (10.92)
92.03 (8.22)
Blood pressure (mmHg)
Systolea
111.32 (9.32)
111.00 (11.73)
Diastolea
68.23 (11.21)
70.00 (11.45)
Body mass indexa (kg/m2)
25.65 (2.75)
25.28 (3.94)
a The numbers were reported as mean (standard deviation)
Anzeige
Sexual function
The mean (SD) total score of FSFI in the OXT group was 19.48 (4.68) before the intervention and 27.50 (5.12) after the intervention, and in the placebo group, it was 22.28 (4.15) before the intervention and 28.14 (4.77) after the intervention. Based on the ANCOVA test with adjusting the baseline value and age, there was no statistically significant difference between groups in terms of the total score of sexual function (AMD: 1.14; 95% CI: -1.28 to 9.16; P= 0.349). Table 2 shows the mean total score of sexual function and all of its domains by the two groups, before and after the intervention.
Table 2
The mean FSFI total score and its dimensions in study groups
Variable (score range)
Oxytocin
n=34
Placebo
n= 30
AMD (95% CI)b
P-value
Mean (SD)a
Mean (SD)a
Desire (1.2-6)
Baseline
2.91 (0.96)
3.42 (0.74)
8 weeks
4.38 (1.00)
4.34 (1.13)
0.32 (0.86 to -0.23)
0.253
Arousal (0-6)
Baseline
1.04 (2.98)
3.49 (0.74)
8 weeks
4.41 (1.09)
4.46 (1.04)
0.32 (0.81 to -0.18)
0.208
Lubrication (0-6)
Baseline
3.34 (0.85)
3.60 (0.8)
8 weeks
4.53 (0.87)
4.65 (0.81)
0.06 (0.47 to -0.36)
0.791
Orgasm (0-6)
Baseline
3.21 (1.00)
2.76 (1.1)
8 weeks
4.46 (1.00)
4.53 (1.03)
0.34 (0.77 to 0.08)
0.114
Satisfaction (0.8-6)
Baseline
3.47 (1.26)
4.39 (1.15)
8 weeks
4.85 (1.16)
5.04 (0.90)
0.29 (0.8 to -0.21)
0.252
Pain (0-6)
Baseline
3.56 (1.24)
3.63 (4.46)
8 weeks
4.88 (1.13)
5.12 (0.98)
0.11 (0.41 to -0.64)
0.664
Total FSFI score (2-36)
Baseline
19.48 (4.67)
22.28 (4.15)
8 weeks
27.50 (5.12)
28.14 (4.77)
1.14 (3.57 to -1.28)
0.349
a Mean (standard deviation)
b Adjusted mean difference (95% confidence interval)
ANCOVA test adjusted for baseline score was used to compare the mean scores at post-intervention
Higher sexual function scores indicate more favorable conditions
Sexual satisfaction
The mean (SD) sexual satisfaction was 98.35 (17.64) before the intervention and 106.44 (21.7) after the intervention in the OXT group and in the placebo group, it was 109.37 (15.94) before the intervention and 113.23 (16.48) after the intervention. After the intervention, there was no statistically significant difference between the two groups after adjusting the baseline value and age (it was borderline evidence in terms of sexual satisfaction) (AMD: 5.01; 95% CI: -0.53 to 10.56; P= 0.075). Among the five domains, only sexual contentment was significantly higher in the OXT group compared to the placebo group (AMD: 1.56; 95% CI: 0.29 to 2.83; P = 0.017). Table 3 shows the total mean sexual satisfaction and all of its domains by the groups.
Table 3
The mean sexual satisfaction total score and its dimensions in study groups
Variable (Score range)
Oxytocin
n= 34
Placebo
n= 30
AMD )95% CI)b
P-value
Mean (SD)a
Mean (SD)a
Contentment (6-30)
Baseline
19.21 (4.33)
22.7 (4.6)
8 weeks
21.56 (3.98)
23.17 (4.62)
1.56 (2.83 to 0.29)
0.017
Communication (6-30)
Baseline
20.50 (3.49)
22.7 (3.39)
8 weeks
21.23 (4.42)
23.40 (3.52)
0.23 (1.49 to -1.03)
0.716
Coping (6-30)
Baseline
18.85 (5.21)
22.13 (4.31)
8 weeks
19.68 (5.45)
22.27 (4.42)
0.12 (1.45 to -1.21 )
0.856
Relation concern (6-30)
Baseline
20.26 (4.39)
21.53 (5.17)
8 weeks
22.71 (8.65)
22.27 (4.93)
1.64 (4.67 to -1.32)
0.271
Personal concern (6-30)
Baseline
19.53 (5.42)
20.23 (5.84)
8 weeks
21.26 (5.59)
21.70 (5.11)
0.47 (1.822 to 0.9 )
0.498
Total Sexual Satisfaction (30-150)
Baseline
98.35 (17.64)
109.37 (15.94)
8 weeks
106.44 (21.7)
113.2 (16.48)
5.01 (10.56 to -0.53)
0.075
a Mean (Standard Deviation)
b Adjusted mean difference (95% confidence interval)
ANCOVA test adjusted for baseline score was used to compare the mean scores at post-intervention
Higher scores indicate high sexual satisfaction
Depression
The mean (SD) depression score was 6.32 (3.8) before the intervention and 4.59 (2.40) after the intervention in the OXT group and in the placebo group, it was 7.03 (5.16) before the intervention and 6.63 (2.43) after the intervention. After the intervention, the mean depression score after adjusting the baseline value and age statistically lower in the OXT group than the placebo group (AMD: -1.90; 95% CI: -1.27 to -2.54; P < 0.001) (Table 4). The results of Mann Whitney U test showed statistically significant difference between the groups in terms of the change in depression score (EPDS at 8 weeks - EPDS at baseline) (P < 0.001).
Table 4
The mean depression score in study groups
Variable (Score range)
Oxytocin
n= 34
Placebo
n= 30
AMD (95% CI)b
P-value
Mean (SD)a
Mean (SD)a
Depression (0-30)
Baseline
6.32 (3.8)
7.03 (5.16)
8 weeks
4.59 (2.40)
6.63 (2.43)
-1.90 (-1.27 to -2.54)
<0.001
a Mean (standard deviation)
b Adjusted mean difference (95% confidence interval)
ANCOVA test adjusted for baseline score was used to compare the mean scores at post-intervention
The higher scores indicate the more severe condition
Subgroup analysis based on the delivery type
In both study groups, there was no statistically significant difference between the two subgroups of women with vaginal delivery and cesarean delivery in terms of mean total scores of FSFI, sexual satisfaction and depression. Also, the interaction between study groups and delivery types was not significant (P > 0.05) (Table 5).
Table 5
Subgroup analysis of outcomes based on the delivery type
Variable (Score range)
Baseline
Post-intervention
Vaginal compared to cesarean delivery
AMD (95% CI)a
Interaction between study groups and delivery types
(P-value)
Vaginal delivery
(n= 27)
Cesarean delivery
(n= 37)
Vaginal delivery
(n= 27)
Cesarean delivery
(n= 37)
Total FSFI score (2-36)
0.507
Oxytocin (n= 34)
20.8 (4.3)
18.9 (4.8)
26.1 (5.9)
28.1 (4.8)
-3.1 (-6.5 to 0.4)
Placebo (n= 30)
21.7 (4.1)
23.0 (4.3)
26.6 (4.4)
30.1 (4.7)
-2.9 (-6.2 to 0.3)
Total sexual satisfaction (30-150)
0.810
Oxytocin (n= 34)
93.5 (19.7)
100.4 (16.7)
100.7 (23.2)
108.8 (21.1)
-1.1 (-10.8 to 8.5)
Placebo (n= 30)
114.0 (13.9)
103.3 (16.9)
116.8 (14.0)
108.6 (18.9)
-2.1 (-7.8 to 3.5)
Depression (0-30)
0.437
Oxytocin (n= 34)
7.0 (4.2)
7.3 (3.1)
4.3 (2.3)
4.7 (2.0)
-0.2 (-1.1 to 0.6)
Placebo (n= 30)
6.6 (3.2)
8.5 (3.0)
6.0 (2.5)
7.4 (2.1)
-0.1 (-1.3 to 1.0)
The data present mean (standard deviation) unless otherwise indicated
a Adjusted mean difference (95% Confidence Interval)
ANCOVA test with adjusting for baseline score was used to compare the mean scores of outcomes between two types of delivery
For FSFI and sexual satisfaction, the higher score indicate the better condition and for depression, the higher scores indicate the more severe condition
Side Effects
One participant in the OXT group and one participant in the placebo group reported mild uterine contraction and one person in the placebo group reported vaginal burning sensations. All participants in the two groups used their medication (OXT or placebo) regularly.
Discussion
This trial found no evidence of a significant effect of OXT on the primary outcome (sexual function), but indicated some benefits on wellbeing and possibly on sexual satisfaction”.
In the present research, no evidence was found of an effect of OXT on the sexual function. We found 6 studies examining the effects of intranasal OXT on the sexual function of men and women. Even though in these studies the intranasal OXT resulted in the improvement of disparate parameters of sexual function in men and women, these changes were not statistically significant in comparison to the placebo group. Merely in some studies, it had considerable effects on the intensity of orgasm and the increase of the heart rate caused by orgasm in men [23‐26, 35‐37]. In the present research, placebo manifested considerable effects, which can be due to the beneficial effects of the placebo gel. The results of the present research correspond to the results of the study by Mitchell et al. (2018). They assigned 302 healthy post-menopausal women who were sexually active and had mild to severe symptoms of atrophic vaginitis into three groups; receiving vaginal estradiol, over-the-counter lubricant gel, or placebo gel. Surprisingly, the three groups manifested no statistically significant differences [38]. In accordance with the meta-analysis results of a systematic review, a considerable placebo effect has been reported in most clinical trials on female sexual function disorder. This demonstrates that 67.7% of the therapeutic effects in FSD were related to the placebo [39]. Another study by Shaughnessy et al. [40], revealed that vaginal estrogen has no superiority over lubricant placebo gel.
The results of the present research demonstrated that there was no significant difference between the two groups in terms of mean total score of sexual satisfaction and its subdomain except contentment domain. Sexual satisfaction requires normal sexual function on the basis of the stages of correspondence to the sexual stimuli (sexual desire, arousal, orgasm, and resolution) [41].
Furthermore, the results of the present research demonstrated that OXT significantly leads to the improvement of depression. The results of a study showed that intrapartum synthetic oxytocin predicted a significantly lower risk of postpartum depression [42]. Since, there is a bilateral relationship between sexual function and depression [8‐10], it was expected that the effect of OXT on depression to be mediated through its effect on sexual function. As in this study, no evidence was found for the effects of OXT gel in the improvement of sexual function, it may be a direct effect (hormonal) of OXT on wellbeing. Given the results of some review studies in postpartum mothers and people with major depressive disorder reveal that there is a negative relationship between the severity of depression and the level of plasma OXT [43‐45], it is suggested that OXT plasma levels to be analysed after its intravaginal administration.
During the postpartum, the level of estrogen drops due to the sudden discontinuation of placental estrogen and high levels of prolactin hormone (as a potential antagonist in the secretion of ovary estrogen) [46, 47]. This induced systematic hypoestrogenism can cause urogenital atrophy [48]. Therefore, managing atrophic vaginitis is crucial in order to preserve sexual and vaginal health and to prevent FSD. However, management of atrophic vaginitis in breastfeeding women requires a bilateral view of both mother and the infant. In addition, there are several restrictions in the systematic prescription of disparate chemical and herbal drugs for breastfeeding mothers since there is not enough information regarding the amount of secretion of the drug in mother’s milk and its effect on the milk [49‐51]. Even though the standard treatment of atrophic vaginitis in breastfeeding mothers (like menopausal women) is systematic estrogen, it affects the volume of a mother’s milk, thus, the best therapeutic option for reducing or improving atrophic vaginitis in breastfeeding women are the topical products (vaginal) not the systematic products [48, 52]. Another important factor is that some medicinal vaginal creams (not just for lubricant effects) can weaken the latex in people who use barrier methods for preventing pregnancy. Therefore, the most common methods for the management of atrophic vaginitis in breastfeeding women are water-based lubricant vaginal gels [49, 53, 54].
Limitations, strengths and implications for practice
The present research is the first study to examine the effects of OXT vaginal gel on sexual function in breastfeeding mothers while other studies focused on menopausal women. The strengths of this study include randomization, triple blinding, and no attrition resulting in low risk of bias. In the present research, standard and valid questionnaires were used for assessment of the outcomes due to the financial limitations. However, examining the laboratory criteria such as vaginal maturation could be helpful in determining the effectiveness of OXT and the subjective criteria (questionnaires) alone may not be sufficient for assessment of effectiveness of a drug. Small sample size was another limitation of this study. It is difficult to know whether the “non-significant results” are due to a lack of treatment effect, or a lack of power.
In future clinical trials, assessment of OXT effect in other women with atrophic vaginitis and sexual dysfunction such as women suffering from premature ovarian failure (POF) or women suffering from atrophic vaginitis due to abdominal or pelvic radiotherapy or chemotherapy could be considered. As no definitive conclusion can be drawn from this trial, further trials of OXT in breastfeeding women are recommended.
Conclusions
No evidence was found for the effects of OXT gel in the improvement of sexual function, even though, OXT significantly improved sexual satisfaction in the domain of contentment, and improved the symptoms of depression in comparison to the placebo group. However, a definite conclusion requires more research in this regard.
Acknowledgements
This study was extracted from the master’s thesis in obstetrics. Hereby, we appreciate all participating in this study, especially the Caspian Tamin Pharmaceutical Company for providing raw materials of OXT as well as all participants of this study.
Declarations
Ethics approval and consent to participate
This research has been approved by the Ethics Committee of the Tabriz University of Medical Sciences, Tabriz, Iran (code number: IR.TBZMED.REC.1396.715). All subjects were ensured about the matter of confidentiality and signed the informed written consent form. All methods were performed in accordance with the Declaration of Helsinki.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.
Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.
Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.
Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.
Update Gynäkologie
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.
